Reported Earlier, iRhythm's GUARD-AF Trial Highlights Zio XT Patch for AF Screening in Older Adults: ESC Presentation
Portfolio Pulse from Benzinga Newsdesk
iRhythm Technologies presented the GUARD-AF trial results at the ESC Congress 2024, highlighting the Zio XT patch's role in AF screening for older adults. The trial, sponsored by Bristol-Myers Squibb-Pfizer Alliance, showed increased AF diagnosis but no significant difference in stroke hospitalization.
September 03, 2024 | 7:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
iRhythm Technologies' Zio XT patch was highlighted in the GUARD-AF trial, showing increased AF diagnosis in older adults. However, no significant difference in stroke hospitalization was observed.
The GUARD-AF trial results presented at the ESC Congress 2024 highlight the effectiveness of iRhythm's Zio XT patch in diagnosing AF in older adults. Although the trial did not show a significant difference in stroke hospitalization, the increased diagnosis rate is a positive outcome for iRhythm's product. This could lead to increased adoption and sales of the Zio XT patch, positively impacting iRhythm's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90